{
    "ticker": "SGBLY",
    "name": "Sangamo Therapeutics, Inc.",
    "description": "Sangamo Therapeutics, Inc. is a leading biotechnology company focused on developing genomic therapies for genetic diseases, cancer, and other serious conditions. Founded in 1995 and headquartered in Richmond, California, Sangamo is pioneering the use of its proprietary platform in gene editing and gene regulation to advance innovative treatments. The company primarily employs its Zinc Finger Protein (ZFP) technology to create targeted therapies that can modify genes at precise locations, enabling the potential to correct genetic defects or alter gene expression. Sangamo's pipeline includes programs for rare genetic disorders, hemophilia, and neurodegenerative diseases, among others. Its collaborations with major pharmaceutical companies and research institutions aim to accelerate the application of its technologies in clinical settings. Committed to scientific excellence and patient-centric solutions, Sangamo strives to transform the treatment landscape for patients suffering from debilitating diseases. The company\u2019s vision encompasses not only therapeutic advancements but also a strong ethical framework in delivering genetic therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Richmond, California, USA",
    "founded": "1995",
    "website": "https://www.sangamo.com",
    "ceo": "Beth McGrath",
    "social_media": {
        "twitter": "https://twitter.com/SangamoTx",
        "linkedin": "https://www.linkedin.com/company/sangamo-therapeutics/"
    },
    "investor_relations": "https://investors.sangamo.com",
    "key_executives": [
        {
            "name": "Beth McGrath",
            "position": "CEO"
        },
        {
            "name": "Katherine B. H. F. L. H. N. K. Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "SB-525",
                "ST-400"
            ]
        },
        {
            "category": "Gene Editing",
            "products": [
                "ZFP Technology"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sangamo Therapeutics, Inc. | Pioneering Gene Therapy and Editing",
        "meta_description": "Explore Sangamo Therapeutics, Inc., a leader in genomic therapies focused on innovative solutions for genetic diseases and serious conditions.",
        "keywords": [
            "Sangamo Therapeutics",
            "Gene Therapy",
            "Gene Editing",
            "Biotechnology",
            "Zinc Finger Proteins",
            "Genetic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Sangamo Therapeutics specialize in?",
            "answer": "Sangamo Therapeutics specializes in developing genomic therapies for genetic diseases and cancer using gene editing technologies."
        },
        {
            "question": "Who is the CEO of Sangamo Therapeutics?",
            "answer": "Beth McGrath is the CEO of Sangamo Therapeutics, Inc."
        },
        {
            "question": "Where is Sangamo headquartered?",
            "answer": "Sangamo is headquartered in Richmond, California, USA."
        },
        {
            "question": "What technologies does Sangamo use?",
            "answer": "Sangamo uses its proprietary Zinc Finger Protein (ZFP) technology for gene editing and gene regulation."
        },
        {
            "question": "When was Sangamo founded?",
            "answer": "Sangamo was founded in 1995."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "NTLA",
        "PGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ]
}